Results 21 to 30 of about 31,381 (233)

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

Cancers, 2022
Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu, Leloup, Ludovic, Parat, Fabrice, Messé, Mélissa, Pagano, Alessandra, Kovacic, Hervé   +5 more
openaire   +2 more sources

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

BMC Cancer, 2020
Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses.
Xia Liao, Ge Song, Zihan Xu, Yang Bu, Fan Chang, Fengan Jia, Xuelian Xiao, Xuejiao Ren, Mei Zhang, Qingan Jia   +9 more
doaj   +1 more source

Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

Signal Transduction and Targeted Therapy, 2022
Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance.
Yimin Li, Yaqi Gan, Jiaxin Liu, Juanni Li, Zhengwei Zhou, Ruotong Tian, Ruizheng Sun, Jiaqi Liu, Qing Xiao, Yuanyuan Li, Pengyan Lu, Yulong Peng, Yuqian Peng, Guang Shu, Gang Yin   +14 more
doaj   +1 more source

Targeting the NSUN2-DHODH axis reverses ferroptosis resistance and oxaliplatin resistance in colorectal cancer. [PDF]

Front Pharmacol
Background Oxaliplatin (OXA) is a standard chemotherapy for advanced colorectal cancer (CRC), yet acquired resistance frequently limits its efficacy. Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a promising strategy to overcome chemoresistance.
Zhang J, Shen J, Zeng T, Gao C, Sheng B, Li J, Zeng W, Shen J, Shen C, Wang J, Wang J.   +10 more
europepmc   +4 more sources

WBSCR22 confers oxaliplatin resistance in human colorectal cancer [PDF]

Scientific Reports, 2017
AbstractHuman WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly elevated in human colorectal cancer (CRC) tissue. WBSCR22 could be served as an independent risk
Yan, Dongmei, Tu, Linglan, Yuan, Haining, Fang, Jianfei, Cheng, Liyan, Zheng, Xiaoliang, Wang, Xiaoju   +6 more
openaire   +2 more sources

The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer [PDF]

Frontiers in Molecular Biosciences, 2021
BackgroundColorectal cancer (CRC) is estimated to be one of the most common cancers and the leading cause of cancer-related death worldwide. SOX9 is commonly overexpressed in CRC and participates in drug resistance. In addition, DNA damage repair confers resistance to anticancer drugs.
Yiqiang Liu, Yiqiang Liu, Hong Wu, Tao Luo, Qiyu Luo, Ziyu Meng, Ying Shi, Feifei Li, Feifei Li, Mingxin Liu, Xinhao Peng, Junjie Liu, Chuan Xu, Weizhong Tang   +13 more
openaire   +3 more sources

A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

Frontiers in Oncology, 2021
Numerous colon cancer cases are resistant to chemotherapy based on oxaliplatin and suffer from relapse. A number of survival- and prognosis-related biomarkers have been identified based on database mining for patients who develop drug resistance, but the
Qiu Lin, Li Luo, Hua Wang
doaj   +1 more source

A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer

Cell Death and Disease, 2021
Long noncoding RNAs (lncRNAs) have emerged as a new class of regulatory molecules implicated in therapeutic resistance, yet the mechanisms underlying lncRNA-mediated oxaliplatin resistance in colorectal cancer (CRC) are poorly understood.
Xuan Deng, Fanyang Kong, Si Li, Haoqin Jiang, Liu Dong, Xiao Xu, Xinju Zhang, Hong Yuan, Ying Xu, Yimin Chu, Haixia Peng, Ming Guan   +11 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance [PDF]

ecancermedicalscience, 2010
Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for the treatment of colorectal cancer has become increasingly ...
Seetharam, RN, Sood, A, Goel, S
openaire   +2 more sources